FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200438338> ?p ?o ?g. }

• W4200438338 endingPage "S617" @default.
• W4200438338 startingPage "S616" @default.
• W4200438338 abstract "Abstract Background Risk factors (RFs) for pneumococcal disease (PD) in immunocompetent individuals include comorbidities, behavioral habits, or living in a community with increased risk of PD transmission. RF stacking of comorbidities is associated with a higher incidence of PD, approaching that of immunocompromised individuals. Pneumococcal vaccination of certain adults is recommended with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) alone/sequentially with pneumococcal conjugate vaccine (PCV). V114, an investigational 15-valent PCV, contains 2 epidemiologically important serotypes (STs), 22F and 33F, in addition to the 13 STs in 13-valent PCV (PCV13). Methods PNEU-DAY was a Phase 3 study evaluating V114 or PCV13 administered on Day 1, and PPSV23 given 6 months later, in adults aged 18–49 years with or without RFs. This subgroup analysis assessed safety, tolerability, and immunogenicity of V114 and PCV13 based on the number of baseline PD RFs, which included chronic liver, lung, and heart disease, diabetes mellitus, tobacco use, and alcohol consumption. Adverse events (AEs; overall and solicited) were collected after each vaccination. Immunogenicity assessment was based on ST-specific opsonophagocytic activity (OPA) at 30 days after each vaccination. Subgroup analyses were conducted by RF group (0, 1, or ≥2 RFs for PD). Results Among the 1515 participants randomized to V114 (n=1135) or PCV13 (n=380), 25.2% had no RFs, 54.7% had 1 RF and 20.1% had ≥2 RFs for PD at baseline. The proportions of participants with solicited AEs following V114/PCV13 and PPSV23 were comparable across the 3 subgroups, with injection-site pain, myalgia, and fatigue being the most common. V114 and PCV13 were immunogenic in all subgroups based on OPA geometric mean titers (GMTs) at 30 days post-vaccination for the 13 shared STs (Figure); in addition, V114 induced a robust immune response to the 2 unique STs (22F, 33F) in all subgroups. PPSV23 following PCV was immunogenic for all 15 STs contained in V114 across all subgroups. Figure. Serotype-specific OPA GMTs at baseline and 30 days post-vaccination with V114 and PCV13 by number of baseline risk factors (per-protocol population) Conclusion V114 administered alone/sequentially with PPSV23 is well tolerated and immunogenic for all 15 vaccine STs, including those not contained in PCV13, in immunocompetent adults aged 18–49 years, regardless of the number of baseline RFs. Disclosures Laura Hammitt, MD, MedImmune (Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support)Merck & Co., Inc. (Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support)Novavax (Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support)Pfizer (Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support) Francisco J. Pasquel, MD, MPH, Boehringer Ingelheim (Consultant)Dexcom (Grant/Research Support)Eli Lilly & Company (Consultant)Insulet (Grant/Research Support)Merck & Co., Inc. (Consultant, Grant/Research Support) K. Rajender Reddy, MD, BMS (Grant/Research Support)Deciphera (Advisor or Review Panel member)Gilead (Grant/Research Support)Grifols (Grant/Research Support)HCC-TARGET (Grant/Research Support)Intercept (Grant/Research Support)Mallinckrodt (Grant/Research Support, Advisor or Review Panel member)NASH-TARGET (Grant/Research Support)Pfizer (Advisor or Review Panel member)Sequana (Grant/Research Support) Ron Dagan, MD, Medimmune/AstraZeneca (Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support)MSD (Consultant, Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Research Grant or Support, Speaker’s Bureau)Pfizer (Consultant, Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Research Grant or Support, Speaker’s Bureau) Rachel Dawson, D.O. MPH, Merck & Co., Inc. (Employee, Shareholder) Jennifer McCauley, BSc, Merck & Co., Inc. (Employee) Kyeongmi Cheon, Ph.D., Merck & Co., Inc. (Employee, Shareholder) Alison Pedley, PhD, Merck & Co., Inc. (Employee) Tina Sterling, BS, Merck & Co., Inc. (Employee, Shareholder) Gretchen Tamms, B.S., Merck Sharp and Dohme (Employee, Shareholder) Luwy Musey, MD, Merck & Co., Inc. (Employee) Ulrike K. Buchwald, MD, MS, Merck & Co., Inc. (Employee)TB Alliance (Employee)" @default.
• W4200438338 created "2021-12-31" @default.
• W4200438338 creator A5004928964 @default.
• W4200438338 creator A5010135037 @default.
• W4200438338 creator A5011107229 @default.
• W4200438338 creator A5013975567 @default.
• W4200438338 creator A5018611179 @default.
• W4200438338 creator A5029442618 @default.
• W4200438338 creator A5044678931 @default.
• W4200438338 creator A5052885935 @default.
• W4200438338 creator A5054885186 @default.
• W4200438338 creator A5056210917 @default.
• W4200438338 creator A5063337323 @default.
• W4200438338 creator A5077108679 @default.
• W4200438338 creator A5077502906 @default.
• W4200438338 creator A5080926064 @default.
• W4200438338 creator A5081629035 @default.
• W4200438338 creator A5085209734 @default.
• W4200438338 creator A5086250528 @default.
• W4200438338 date "2021-11-01" @default.
• W4200438338 modified "2023-09-25" @default.
• W4200438338 title "1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors" @default.
• W4200438338 doi "https://doi.org/10.1093/ofid/ofab466.1244" @default.
• W4200438338 hasPublicationYear "2021" @default.
• W4200438338 type Work @default.
• W4200438338 citedByCount "1" @default.
• W4200438338 countsByYear W42004383382022 @default.
• W4200438338 crossrefType "journal-article" @default.
• W4200438338 hasAuthorship W4200438338A5004928964 @default.
• W4200438338 hasAuthorship W4200438338A5010135037 @default.
• W4200438338 hasAuthorship W4200438338A5011107229 @default.
• W4200438338 hasAuthorship W4200438338A5013975567 @default.
• W4200438338 hasAuthorship W4200438338A5018611179 @default.
• W4200438338 hasAuthorship W4200438338A5029442618 @default.
• W4200438338 hasAuthorship W4200438338A5044678931 @default.
• W4200438338 hasAuthorship W4200438338A5052885935 @default.
• W4200438338 hasAuthorship W4200438338A5054885186 @default.
• W4200438338 hasAuthorship W4200438338A5056210917 @default.
• W4200438338 hasAuthorship W4200438338A5063337323 @default.
• W4200438338 hasAuthorship W4200438338A5077108679 @default.
• W4200438338 hasAuthorship W4200438338A5077502906 @default.
• W4200438338 hasAuthorship W4200438338A5080926064 @default.
• W4200438338 hasAuthorship W4200438338A5081629035 @default.
• W4200438338 hasAuthorship W4200438338A5085209734 @default.
• W4200438338 hasAuthorship W4200438338A5086250528 @default.
• W4200438338 hasBestOaLocation W42004383381 @default.
• W4200438338 hasConcept C126322002 @default.
• W4200438338 hasConcept C187212893 @default.
• W4200438338 hasConcept C197934379 @default.
• W4200438338 hasConcept C203014093 @default.
• W4200438338 hasConcept C22070199 @default.
• W4200438338 hasConcept C2778375690 @default.
• W4200438338 hasConcept C2778866548 @default.
• W4200438338 hasConcept C2779301066 @default.
• W4200438338 hasConcept C2779664119 @default.
• W4200438338 hasConcept C2780868878 @default.
• W4200438338 hasConcept C2781253189 @default.
• W4200438338 hasConcept C3020803494 @default.
• W4200438338 hasConcept C523546767 @default.
• W4200438338 hasConcept C54355233 @default.
• W4200438338 hasConcept C71924100 @default.
• W4200438338 hasConcept C86803240 @default.
• W4200438338 hasConcept C8891405 @default.
• W4200438338 hasConceptScore W4200438338C126322002 @default.
• W4200438338 hasConceptScore W4200438338C187212893 @default.
• W4200438338 hasConceptScore W4200438338C197934379 @default.
• W4200438338 hasConceptScore W4200438338C203014093 @default.
• W4200438338 hasConceptScore W4200438338C22070199 @default.
• W4200438338 hasConceptScore W4200438338C2778375690 @default.
• W4200438338 hasConceptScore W4200438338C2778866548 @default.
• W4200438338 hasConceptScore W4200438338C2779301066 @default.
• W4200438338 hasConceptScore W4200438338C2779664119 @default.
• W4200438338 hasConceptScore W4200438338C2780868878 @default.
• W4200438338 hasConceptScore W4200438338C2781253189 @default.
• W4200438338 hasConceptScore W4200438338C3020803494 @default.
• W4200438338 hasConceptScore W4200438338C523546767 @default.
• W4200438338 hasConceptScore W4200438338C54355233 @default.
• W4200438338 hasConceptScore W4200438338C71924100 @default.
• W4200438338 hasConceptScore W4200438338C86803240 @default.
• W4200438338 hasConceptScore W4200438338C8891405 @default.
• W4200438338 hasIssue "Supplement_1" @default.
• W4200438338 hasLocation W42004383381 @default.
• W4200438338 hasLocation W42004383382 @default.
• W4200438338 hasOpenAccess W4200438338 @default.
• W4200438338 hasPrimaryLocation W42004383381 @default.
• W4200438338 hasRelatedWork W1581419896 @default.
• W4200438338 hasRelatedWork W1597325035 @default.
• W4200438338 hasRelatedWork W2069691422 @default.
• W4200438338 hasRelatedWork W2396129074 @default.
• W4200438338 hasRelatedWork W2594412325 @default.
• W4200438338 hasRelatedWork W2598503260 @default.
• W4200438338 hasRelatedWork W2963060457 @default.
• W4200438338 hasRelatedWork W3014155287 @default.
• W4200438338 hasRelatedWork W3107791741 @default.
• W4200438338 hasRelatedWork W4243081340 @default.
• W4200438338 hasVolume "8" @default.
• W4200438338 isParatext "false" @default.
• W4200438338 isRetracted "false" @default.

• next